Publications by authors named "Thanongsak Suwannathen"
Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG).
Thanawat Rattanathammethee Lalita Norasetthada Udomsak Bunworasate Kitsada Wudhikarn Jakrawadee Julamanee Thanongsak Suwannathen
Ann Hematol
July 2023
Article Synopsis
- Relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) is tough to treat, and there's a need for better therapies; polatuzumab vedotin (Pola), combined with bendamustine-rituximab (BR), has recently been approved for patients.
- A study in Thailand included 35 patients treated with Pola, showing a 62.8% overall response rate (ORR) and survival outcomes better than 180 patients receiving non-Pola therapies.
- Despite some serious adverse events reported, they were manageable, indicating that Pola-based treatment could be a promising option for R/R DLBCL patients with limited alternatives.